CLYM: Advancing two antibody assets in renal and autoimmune diseases, with pivotal trials ahead
Two antibody programs are advancing in immune-mediated diseases, with CLYM-116 showing best-in-class potential in IgAN and budoprutug demonstrating strong efficacy in PMN and ITP. Multiple pivotal trials and data readouts are expected through 2025, supported by a strong financial position.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.